Pharma & Healthcare
Global Long-acting Anti-HIV Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 553960
- Pages: 130
- Figures: 126
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting Anti-HIV Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
ViiV Healthcare
Janssen Pharmaceuticals
Gilead Sciences
Theratechnologies
Segment by Type
Single Drug
Combination Preparation
Segment by Application
HIV Prevention
HIV Treatment
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Long-acting Anti-HIV Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting Anti-HIV Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
ViiV Healthcare
Janssen Pharmaceuticals
Gilead Sciences
Theratechnologies
Segment by Type
Single Drug
Combination Preparation
Segment by Application
HIV Prevention
HIV Treatment
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Long-acting Anti-HIV Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Long-acting Anti-HIV Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long-acting Anti-HIV Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Single Drug
1.2.3 Combination Preparation
1.3 Market Segmentation by Application
1.3.1 Global Long-acting Anti-HIV Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 HIV Prevention
1.3.3 HIV Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting Anti-HIV Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Long-acting Anti-HIV Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Long-acting Anti-HIV Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Long-acting Anti-HIV Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Long-acting Anti-HIV Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Long-acting Anti-HIV Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Single Drug Market Size by Manufacturers
3.5.2 Combination Preparation Market Size by Manufacturers
3.6 Global Long-acting Anti-HIV Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long-acting Anti-HIV Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Long-acting Anti-HIV Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long-acting Anti-HIV Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Long-acting Anti-HIV Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long-acting Anti-HIV Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long-acting Anti-HIV Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Long-acting Anti-HIV Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long-acting Anti-HIV Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long-acting Anti-HIV Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Corporation Information
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.1.4 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Product in 2024
11.1.6 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Application in 2024
11.1.7 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.1.8 ViiV Healthcare Long-acting Anti-HIV Drugs SWOT Analysis
11.1.9 ViiV Healthcare Recent Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Corporation Information
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.2.4 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Product in 2024
11.2.6 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Application in 2024
11.2.7 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.2.8 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs SWOT Analysis
11.2.9 Janssen Pharmaceuticals Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Product in 2024
11.3.6 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Application in 2024
11.3.7 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Long-acting Anti-HIV Drugs SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Theratechnologies
11.4.1 Theratechnologies Corporation Information
11.4.2 Theratechnologies Business Overview
11.4.3 Theratechnologies Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.4.4 Theratechnologies Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Theratechnologies Long-acting Anti-HIV Drugs Sales by Product in 2024
11.4.6 Theratechnologies Long-acting Anti-HIV Drugs Sales by Application in 2024
11.4.7 Theratechnologies Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.4.8 Theratechnologies Long-acting Anti-HIV Drugs SWOT Analysis
11.4.9 Theratechnologies Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Long-acting Anti-HIV Drugs Industry Chain
12.2 Long-acting Anti-HIV Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Long-acting Anti-HIV Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Long-acting Anti-HIV Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long-acting Anti-HIV Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long-acting Anti-HIV Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Long-acting Anti-HIV Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long-acting Anti-HIV Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Single Drug
1.2.3 Combination Preparation
1.3 Market Segmentation by Application
1.3.1 Global Long-acting Anti-HIV Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 HIV Prevention
1.3.3 HIV Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting Anti-HIV Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Long-acting Anti-HIV Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Long-acting Anti-HIV Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Long-acting Anti-HIV Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Long-acting Anti-HIV Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Long-acting Anti-HIV Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Single Drug Market Size by Manufacturers
3.5.2 Combination Preparation Market Size by Manufacturers
3.6 Global Long-acting Anti-HIV Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long-acting Anti-HIV Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Long-acting Anti-HIV Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long-acting Anti-HIV Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Long-acting Anti-HIV Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long-acting Anti-HIV Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long-acting Anti-HIV Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Long-acting Anti-HIV Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long-acting Anti-HIV Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Long-acting Anti-HIV Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Long-acting Anti-HIV Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long-acting Anti-HIV Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Corporation Information
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.1.4 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Product in 2024
11.1.6 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Application in 2024
11.1.7 ViiV Healthcare Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.1.8 ViiV Healthcare Long-acting Anti-HIV Drugs SWOT Analysis
11.1.9 ViiV Healthcare Recent Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Corporation Information
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.2.4 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Product in 2024
11.2.6 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Application in 2024
11.2.7 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.2.8 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs SWOT Analysis
11.2.9 Janssen Pharmaceuticals Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Product in 2024
11.3.6 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Application in 2024
11.3.7 Gilead Sciences Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Long-acting Anti-HIV Drugs SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Theratechnologies
11.4.1 Theratechnologies Corporation Information
11.4.2 Theratechnologies Business Overview
11.4.3 Theratechnologies Long-acting Anti-HIV Drugs Product Models, Descriptions and Specifications
11.4.4 Theratechnologies Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Theratechnologies Long-acting Anti-HIV Drugs Sales by Product in 2024
11.4.6 Theratechnologies Long-acting Anti-HIV Drugs Sales by Application in 2024
11.4.7 Theratechnologies Long-acting Anti-HIV Drugs Sales by Geographic Area in 2024
11.4.8 Theratechnologies Long-acting Anti-HIV Drugs SWOT Analysis
11.4.9 Theratechnologies Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Long-acting Anti-HIV Drugs Industry Chain
12.2 Long-acting Anti-HIV Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Long-acting Anti-HIV Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Long-acting Anti-HIV Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long-acting Anti-HIV Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long-acting Anti-HIV Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Long-acting Anti-HIV Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Long-acting Anti-HIV Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Long-acting Anti-HIV Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Long-acting Anti-HIV Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Long-acting Anti-HIV Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Long-acting Anti-HIV Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Long-acting Anti-HIV Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Long-acting Anti-HIV Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Long-acting Anti-HIV Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Anti-HIV Drugs as of 2024)
Table 16. Global Long-acting Anti-HIV Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Long-acting Anti-HIV Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Long-acting Anti-HIV Drugs Manufacturing Base and Headquarters
Table 19. Global Long-acting Anti-HIV Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Long-acting Anti-HIV Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Long-acting Anti-HIV Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Long-acting Anti-HIV Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Long-acting Anti-HIV Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Long-acting Anti-HIV Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Long-acting Anti-HIV Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Long-acting Anti-HIV Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Long-acting Anti-HIV Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Long-acting Anti-HIV Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Long-acting Anti-HIV Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Long-acting Anti-HIV Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 37. North America Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 40. Europe Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Long-acting Anti-HIV Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Long-acting Anti-HIV Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. ViiV Healthcare Corporation Information
Table 51. ViiV Healthcare Description and Major Businesses
Table 52. ViiV Healthcare Product Models, Descriptions and Specifications
Table 53. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 55. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 56. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 57. ViiV Healthcare Long-acting Anti-HIV Drugs SWOT Analysis
Table 58. ViiV Healthcare Recent Developments
Table 59. Janssen Pharmaceuticals Corporation Information
Table 60. Janssen Pharmaceuticals Description and Major Businesses
Table 61. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs SWOT Analysis
Table 67. Janssen Pharmaceuticals Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Long-acting Anti-HIV Drugs SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Theratechnologies Corporation Information
Table 78. Theratechnologies Description and Major Businesses
Table 79. Theratechnologies Product Models, Descriptions and Specifications
Table 80. Theratechnologies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Theratechnologies Sales Value Proportion by Product in 2024
Table 82. Theratechnologies Sales Value Proportion by Application in 2024
Table 83. Theratechnologies Sales Value Proportion by Geographic Area in 2024
Table 84. Theratechnologies Long-acting Anti-HIV Drugs SWOT Analysis
Table 85. Theratechnologies Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-acting Anti-HIV Drugs Product Picture
Figure 2. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Single Drug Product Picture
Figure 4. Combination Preparation Product Picture
Figure 5. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. HIV Prevention
Figure 7. HIV Treatment
Figure 8. Long-acting Anti-HIV Drugs Report Years Considered
Figure 9. Global Long-acting Anti-HIV Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 11. Global Long-acting Anti-HIV Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2020-2031)
Figure 13. Global Long-acting Anti-HIV Drugs Sales (2020-2031) & (K Units)
Figure 14. Global Long-acting Anti-HIV Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 15. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2020-2031)
Figure 16. Top 5 and Top 10 Manufacturers Long-acting Anti-HIV Drugs Sales Volume Market Share in 2024
Figure 17. Global Long-acting Anti-HIV Drugs Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Single Drug Revenue Market Share by Manufacturer in 2024
Figure 20. Combination Preparation Revenue Market Share by Manufacturer in 2024
Figure 21. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2020-2031)
Figure 22. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2020-2031)
Figure 23. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2020-2031)
Figure 24. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2020-2031)
Figure 25. North America Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 26. North America Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 28. North America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 29. North America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 31. North America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 32. US Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 33. Canada Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Europe Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 36. Europe Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Europe Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 38. Europe Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 39. Europe Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 40. Europe Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 41. Europe Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. Germany Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. France Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. U.K. Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. Italy Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Russia Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Asia-Pacific Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 48. Asia-Pacific Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Top 8 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 50. Asia-Pacific Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 51. Asia-Pacific Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 52. Asia-Pacific Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 53. Asia-Pacific Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 54. Indonesia Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Japan Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. South Korea Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 57. China Taiwan Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. India Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. Central and South America Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 60. Central and South America Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Central and South America Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 62. Central and South America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 63. Central and South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 64. Central and South America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 65. Central and South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 66. Brazil Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. Argentina Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. Middle East, and Africa Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Middle East and Africa Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Middle East and Africa Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Middle East and Africa Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Middle East and Africa Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Middle East and Africa Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. GCC Countries Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Turkey Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Egypt Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 78. South Africa Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Long-acting Anti-HIV Drugs Industry Chain Mapping
Figure 80. Regional Long-acting Anti-HIV Drugs Manufacturing Base Distribution (%)
Figure 81. Global Long-acting Anti-HIV Drugs Production Market Share by Region (2020-2031)
Figure 82. Long-acting Anti-HIV Drugs Production Process
Figure 83. Regional Long-acting Anti-HIV Drugs Production Cost Structure
Figure 84. Channels of Distribution (Direct Vs Distribution)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
Table 1. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Long-acting Anti-HIV Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Long-acting Anti-HIV Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Long-acting Anti-HIV Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Long-acting Anti-HIV Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Long-acting Anti-HIV Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Long-acting Anti-HIV Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Long-acting Anti-HIV Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Long-acting Anti-HIV Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Long-acting Anti-HIV Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Anti-HIV Drugs as of 2024)
Table 16. Global Long-acting Anti-HIV Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Long-acting Anti-HIV Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Long-acting Anti-HIV Drugs Manufacturing Base and Headquarters
Table 19. Global Long-acting Anti-HIV Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Long-acting Anti-HIV Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Long-acting Anti-HIV Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Long-acting Anti-HIV Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Long-acting Anti-HIV Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Long-acting Anti-HIV Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Long-acting Anti-HIV Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Long-acting Anti-HIV Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Long-acting Anti-HIV Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Long-acting Anti-HIV Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Long-acting Anti-HIV Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Long-acting Anti-HIV Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 37. North America Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 40. Europe Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Long-acting Anti-HIV Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Long-acting Anti-HIV Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Long-acting Anti-HIV Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Long-acting Anti-HIV Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. ViiV Healthcare Corporation Information
Table 51. ViiV Healthcare Description and Major Businesses
Table 52. ViiV Healthcare Product Models, Descriptions and Specifications
Table 53. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 55. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 56. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 57. ViiV Healthcare Long-acting Anti-HIV Drugs SWOT Analysis
Table 58. ViiV Healthcare Recent Developments
Table 59. Janssen Pharmaceuticals Corporation Information
Table 60. Janssen Pharmaceuticals Description and Major Businesses
Table 61. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs SWOT Analysis
Table 67. Janssen Pharmaceuticals Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Long-acting Anti-HIV Drugs SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Theratechnologies Corporation Information
Table 78. Theratechnologies Description and Major Businesses
Table 79. Theratechnologies Product Models, Descriptions and Specifications
Table 80. Theratechnologies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Theratechnologies Sales Value Proportion by Product in 2024
Table 82. Theratechnologies Sales Value Proportion by Application in 2024
Table 83. Theratechnologies Sales Value Proportion by Geographic Area in 2024
Table 84. Theratechnologies Long-acting Anti-HIV Drugs SWOT Analysis
Table 85. Theratechnologies Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-acting Anti-HIV Drugs Product Picture
Figure 2. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Single Drug Product Picture
Figure 4. Combination Preparation Product Picture
Figure 5. Global Long-acting Anti-HIV Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. HIV Prevention
Figure 7. HIV Treatment
Figure 8. Long-acting Anti-HIV Drugs Report Years Considered
Figure 9. Global Long-acting Anti-HIV Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 11. Global Long-acting Anti-HIV Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2020-2031)
Figure 13. Global Long-acting Anti-HIV Drugs Sales (2020-2031) & (K Units)
Figure 14. Global Long-acting Anti-HIV Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 15. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2020-2031)
Figure 16. Top 5 and Top 10 Manufacturers Long-acting Anti-HIV Drugs Sales Volume Market Share in 2024
Figure 17. Global Long-acting Anti-HIV Drugs Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Single Drug Revenue Market Share by Manufacturer in 2024
Figure 20. Combination Preparation Revenue Market Share by Manufacturer in 2024
Figure 21. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2020-2031)
Figure 22. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2020-2031)
Figure 23. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2020-2031)
Figure 24. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2020-2031)
Figure 25. North America Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 26. North America Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 28. North America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 29. North America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 31. North America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 32. US Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 33. Canada Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Europe Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 36. Europe Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Europe Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 38. Europe Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 39. Europe Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 40. Europe Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 41. Europe Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. Germany Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. France Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. U.K. Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. Italy Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Russia Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Asia-Pacific Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 48. Asia-Pacific Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Top 8 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 50. Asia-Pacific Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 51. Asia-Pacific Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 52. Asia-Pacific Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 53. Asia-Pacific Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 54. Indonesia Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Japan Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. South Korea Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 57. China Taiwan Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. India Long-acting Anti-HIV Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. Central and South America Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 60. Central and South America Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Central and South America Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 62. Central and South America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 63. Central and South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 64. Central and South America Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 65. Central and South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 66. Brazil Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. Argentina Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. Middle East, and Africa Long-acting Anti-HIV Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Middle East and Africa Long-acting Anti-HIV Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Middle East and Africa Top 5 Manufacturers Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Middle East and Africa Long-acting Anti-HIV Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. South America Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Middle East and Africa Long-acting Anti-HIV Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Middle East and Africa Long-acting Anti-HIV Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. GCC Countries Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Turkey Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Egypt Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 78. South Africa Long-acting Anti-HIV Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Long-acting Anti-HIV Drugs Industry Chain Mapping
Figure 80. Regional Long-acting Anti-HIV Drugs Manufacturing Base Distribution (%)
Figure 81. Global Long-acting Anti-HIV Drugs Production Market Share by Region (2020-2031)
Figure 82. Long-acting Anti-HIV Drugs Production Process
Figure 83. Regional Long-acting Anti-HIV Drugs Production Cost Structure
Figure 84. Channels of Distribution (Direct Vs Distribution)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232